ESMO: Pazopanib Effective Against Metastatic Renal Cell Carcinoma

Share this content:
(ChemotherapyAdvisor) – Targeted drug pazopanib's efficacy in controlling metastatic renal cell carcinoma (mRCC) is similar to that of sunitinib -- but with lower incidences of patient fatigue and skin sores, according to a randomized, open-label phase 3 clinical study presented at the European Society for Medical Oncology (ESMO) annual meeting in Vienna, Austria.

“The trial showed that pazopanib had similar efficacy (ie, noninferiority) compared to sunitinib in first-line treatment of metastatic renal cell carcinoma,” reported Robert Motzer, MD, of the Memorial Sloan Kettering Cancer Center in New York. “The quality-of-life questionnaires were in favor of pazopanib over sunitinib, and suggested improved tolerability for pazopanib over sunitinib.”

The primary endpoint of the 1,100-patient study was progression-free survival (PFS); secondary endpoints were safety and patient quality of life. For both drugs, the median progression-free survival was slightly more than 10 months (pazopanib [n=557], 10.5 months vs sunitinib [n=553], 10.2 months; HR 0.998 [95% CI: 0.863-1.154]; n.s.).

Objective response rates (ORR) were higher for pazopanib (31% vs 25%; P=0.03), but median overall survival (OS) was similar between the two drugs: OS for pazopanib was 28.4 months, versus 29.3 months for sunitinib (HR 0.91 [95% CI: 0.76-1.08]; n.s.).

Toxicities were similar overall between the two drugs, but hand-foot syndrome and fatigue were less frequent among patients administered pazopanib (fatigue: 55% vs 63%; HR 0.87 [95% CI: 0.79-0.96]; hand-foot syndrome: 29% vs 50%; HR 0.59 [95% CI: 0.50-0.68]). Dyspepsia, hypothyroidism, mucositis, neutropenia, thrombocytopenia and anemia were all less frequent among patients administered pazopanib, as well.

Hypertension was modestly more frequent among patients receiving pazopanib (46% vs 41%; HR 1.14 [95% CI: 1.00-1.31]).

The COMPARZ trial “allows us to define a standard option in the front-line treatment of renal cell carcinoma, because it was proven that pazopanib is non-inferior to sunitinib, commented Maria De Santis, MD, of the Kaiser Franz Josef Hospital in Vienna, who was not a coauthor of the study. “In addition, being treated with pazopanib, patients experienced fewer troublesome side-effects and an increased quality of life.”

ESMO Abstract (#LBA8_PR) 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs